Following on from information provided to NICE by the company in April 2017 the appraisal of Melanoma (advanced, unresectable, metastatic, NRAS mutation positive) – binimetinib [ID833] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
Status | Discontinued |
Technology type | Medicine |
Decision | Selected |
Process | TA |
ID number | 833 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
External Assessment Group | BMJ Evidence Centre, BMJ Group |
Timeline
Key events during the development of the guidance:
Date | Update |
---|---|
21 December 2022 | Discontinued. Following on from information provided to NICE by the company in April 2017 the appraisal of Melanoma (advanced, unresectable, metastatic, NRAS mutation positive) – binimetinib [ID833] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
08 June 2018 | As you will be aware, the Department for Health and Social Care has asked NICE to conduct a Single Technology Appraisal of binimetinib (as monotherapy) for treating NRAS mutant melanoma. However, the company have now advised that they will not be pursuing a marketing authorisation application for binimetinib from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal on its work programme. As this appraisal has been referred to NICE we will continue to monitor any development and will update interested parties if the situation changes |
17 July 2017 | Following on from advice received from the company, NICE has decided to currently suspend this appraisal on its work programme. As this appraisal has been referred we will continue to monitor any development and will update interested parties if or when the situation changes. |
23 June 2017 | Suspended. Awaiting agreement |
08 June 2016 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual